Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sexually Aggressive Behavior Clear all
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Aggressive Behavior in Fragile X Syndome
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 22, 2026, 1:18 AM EDT
Not yet recruiting Not applicable Interventional
View directory record Official record
Conditions
Bullying, Teen Dating Violence
Interventions
iCHAMPS-YVP
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced May 22, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Adolescent, Bullying, Technology, Mental Health
Interventions
STAC-T
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
11 Years and older
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boise, Idaho • University, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 22, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Bullying of Child, Bullying
Interventions
STAC
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
11 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Golden, Colorado • Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced May 22, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Alcohol Consumption, Violence, Domestic, Stress, Psychological, Aggression
Interventions
CBT Text Messaging, Attention Control Text Messaging
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
21 Years and older
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced May 22, 2026, 1:18 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Bullying, Cyberbullying, Substance Use, Substance Abuse
Interventions
LST MS curriculum+ Bullying/Cyberbulling serious game, LST MS curriculum
Behavioral
Lead sponsor
National Health Promotion Associates, Inc.
Industry
Eligibility
11 Years to 14 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced May 22, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Bullying
Interventions
BullyDown, Attention-matched control
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
12 Years to 14 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Clemente, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 22, 2026, 1:18 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Psychological Distress, Suicidal Ideation
Interventions
Flourish
Device
Lead sponsor
Candice Biernesser
Other
Eligibility
11 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Bay Village, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 22, 2026, 1:18 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Sexual Behavior, Alcohol Drinking, Sexual Aggression, Emotions
Interventions
Alcoholic Beverage, Non-alcoholic Beverage, Partner Negative Mood Manipulation, Partner Positive Mood Manipulation
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
21 Years to 30 Years · Male only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced May 22, 2026, 1:18 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 1:18 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Problematic Behavior in Children
Interventions
Not listed
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
8 Years to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced May 22, 2026, 1:18 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cyberbullying
Interventions
IMPACT Intervention, Control: Enhanced Online Resources (EOR)
Behavioral · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced May 22, 2026, 1:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Substance Use, Stress, Relation, Interpersonal, Bullying, Victimisation, Mental Health Issue, Sleep, Inadequate, Social Skills
Interventions
PeerLearning.net
Behavioral
Lead sponsor
Oregon Research Behavioral Intervention Strategies, Inc.
Industry
Eligibility
Not listed
Enrollment
924 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced May 22, 2026, 1:18 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Bullying, Weight, Body, Trauma, Psychological
Interventions
CBT for Weight Bullying
Behavioral
Lead sponsor
Yale University
Other
Eligibility
11 Years to 17 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced May 22, 2026, 1:18 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aggressive NK-cell Leukemia, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Malignancies, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV Infection, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Osteolytic Lesions of Multiple Myeloma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
sunitinib malate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced May 22, 2026, 1:18 AM EDT